215 related articles for article (PubMed ID: 34686682)
1. Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90.
Zhao S; Zhou L; Dicker DT; Lev A; Zhang S; Ross E; El-Deiry WS
Sci Rep; 2021 Oct; 11(1):20871. PubMed ID: 34686682
[TBL] [Abstract][Full Text] [Related]
2. C-Terminal HSP90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1α through the Oxygen-Dependent Degradation Pathway.
Kataria N; Martinez CA; Kerr B; Zaiter SS; Morgan M; McAlpine SR; Cook KM
Cell Physiol Biochem; 2019; 53(3):480-495. PubMed ID: 31486323
[TBL] [Abstract][Full Text] [Related]
3. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.
Azoitei N; Diepold K; Brunner C; Rouhi A; Genze F; Becher A; Kestler H; van Lint J; Chiosis G; Koren J; Fröhling S; Scholl C; Seufferlein T
Cancer Res; 2014 Dec; 74(23):7125-36. PubMed ID: 25297628
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression patterns for Hypoxia-inducible Factor-1α and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors.
Assimakopoulou M; Androutsopoulou C; Zolota V; Matsoukas J
Histol Histopathol; 2016 May; 31(5):535-46. PubMed ID: 26592496
[TBL] [Abstract][Full Text] [Related]
5. JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70.
Zhang D; Li J; Costa M; Gao J; Huang C
Cancer Res; 2010 Jan; 70(2):813-23. PubMed ID: 20068160
[TBL] [Abstract][Full Text] [Related]
6. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
Liu YV; Baek JH; Zhang H; Diez R; Cole RN; Semenza GL
Mol Cell; 2007 Jan; 25(2):207-17. PubMed ID: 17244529
[TBL] [Abstract][Full Text] [Related]
7. COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70.
van de Sluis B; Groot AJ; Vermeulen J; van der Wall E; van Diest PJ; Wijmenga C; Klomp LW; Vooijs M
PLoS One; 2009 Oct; 4(10):e7332. PubMed ID: 19802386
[TBL] [Abstract][Full Text] [Related]
8. Ηypoxia-inducible factor-1α, von Hippel-Lindau protein, and heat shock protein expression in ophthalmic pterygium and normal conjunctiva.
Pagoulatos D; Pharmakakis N; Lakoumentas J; Assimakopoulou M
Mol Vis; 2014; 20():441-57. PubMed ID: 24715760
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
Zhou J; Schmid T; Frank R; Brüne B
J Biol Chem; 2004 Apr; 279(14):13506-13. PubMed ID: 14726529
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101 targets von Hippel-Lindau tumor suppressor (VHL) to induce HIF1α mediated apoptosis and cell cycle arrest in normoxia condition.
Liu N; Xia WY; Liu SS; Chen HY; Sun L; Liu MY; Li LF; Lu HM; Fu YJ; Wang P; Wu H; Gao JX
Sci Rep; 2016 Feb; 6():20489. PubMed ID: 26841847
[TBL] [Abstract][Full Text] [Related]
11. microRNA-222-Mediated VHL Downregulation Facilitates Retinoblastoma Chemoresistance by Increasing HIF1α Expression.
Li C; Zhao J; Sun W
Invest Ophthalmol Vis Sci; 2020 Aug; 61(10):9. PubMed ID: 32756923
[TBL] [Abstract][Full Text] [Related]
12. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1α and hierarchical quality control of pVHL via chaperone system.
Ni J; Ni A
PLoS One; 2021; 16(7):e0248019. PubMed ID: 34329303
[TBL] [Abstract][Full Text] [Related]
14. Immunophilin-ligands FK506 and CsA inhibit HIF1alpha expression by a VHL- and ubiquitin-independent mechanism.
Kong X; Lin Z; Caro J
FEBS Lett; 2006 Nov; 580(26):6182-6. PubMed ID: 17067582
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha.
Kong X; Lin Z; Liang D; Fath D; Sang N; Caro J
Mol Cell Biol; 2006 Mar; 26(6):2019-28. PubMed ID: 16507982
[TBL] [Abstract][Full Text] [Related]
16. Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium.
Kawanami D; Mahabeleshwar GH; Lin Z; Atkins GB; Hamik A; Haldar SM; Maemura K; Lamanna JC; Jain MK
J Biol Chem; 2009 Jul; 284(31):20522-30. PubMed ID: 19491109
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.
Isaacs JS; Jung YJ; Mimnaugh EG; Martinez A; Cuttitta F; Neckers LM
J Biol Chem; 2002 Aug; 277(33):29936-44. PubMed ID: 12052835
[TBL] [Abstract][Full Text] [Related]
18. TCTP increases stability of hypoxia-inducible factor 1α by interaction with and degradation of the tumour suppressor VHL.
Chen K; Chen S; Huang C; Cheng H; Zhou R
Biol Cell; 2013 May; 105(5):208-218. PubMed ID: 23387829
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
20. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
